Kiora Pharmaceuticals, Inc

Kiora Pharmaceuticals Inc. is a U.S.-based specialty clinical-stage ophthalmology company developing small-molecule therapies for retinal and inflammatory eye diseases. Its pipeline centers on KIO-301, KIO-104 and KIO-101, with the company still in development mode and reliant on external financing and partnering to advance programs toward commercialization.

−100,0 %

5.99

5.99

— Kiora Pharmaceuticals, Inc
%
KIO-30110% A vision-restoring small molecule photoswitch being developed for late-stage retinal degenerative diseases.
KIO-10420% An intravitreal DHODH inhibitor in clinical development for retinal inflammatory diseases.
KIO-1015% A topical eye-drop formulation of the KIO-104 molecule being positioned for partnership.
Collaboration and licensing revenue65% Upfront and milestone-related revenue from partnering agreements such as the TOI license.

Kiora does not sell commercial products broadly today; its current counterparties are pharmaceutical partners, clinical...

  • Pharmaceutical licensing partnersprimary

    Buy rights to KIO-301/KIO-101 or other assets to fund development and access the science.

  • Clinical trial ecosystemprimary

    Investigators, hospitals and research centers that enroll patients and generate clinical data.

  • Retina specialistssecondary

    Would prescribe KIO-301 if approved for inherited retinal degeneration.

  • Uveitis and inflammatory eye disease specialistssecondary

    Would use KIO-104 for retinal inflammatory indications if approved.

  • Patients with rare ophthalmic diseasessecondary

    End users of the therapies, especially those with limited treatment options.

Kiora is headquartered in the United States and its development programs are intended for major regulated markets...

  • •United States is the core operating base and primary capital market
  • •Clinical development targets the U.S. and Europe for registration studies
  • •Partnering can extend programs outside the U.S. territory
  • •No meaningful commercial manufacturing footprint disclosed
  • •Geographic exposure is mainly regulatory and trial-enrollment related

Kiora’s strategy is to advance a small number of ophthalmology assets through clinical proof-of-concept while using...

01
Advance KIO-301 clinical developmentmedium-term

KIO-301 is the most differentiated asset and could address unmet need in inherited retinal disease.

02
Enroll and generate data for KIO-104short-term

Clinical validation in retinal inflammation is needed to support partnering or future commercialization.

03
Partner KIO-101short-term

The company has paused internal development and wants a partner to fund further work.

04
Secure additional financingshort-term

The company needs capital to continue operations and avoid delaying or terminating programs.

Kiora is a development-stage biotech with no meaningful commercial revenue, so its business depends on successful...

high

Financing risk

The company needs additional capital to fund operations and development, and may not obtain it on acceptable terms.

Scope
Equity, debt, grants and collaboration proceeds
Materiality
high
high

Clinical development failure

Pipeline value depends on positive efficacy and safety data in small, specialized ophthalmic indications.

Scope
KIO-301, KIO-104, KIO-101
Materiality
high
high

Regulatory approval risk

Even promising data may not translate into approvable endpoints or market authorization.

Scope
U.S., Europe and other major regions
Materiality
high
high

Going-concern and burn-rate risk

The company has a history of losses and negative cash flows, increasing sensitivity to spending changes.

Scope
Operating expenses and runway
Materiality
high
medium

Partnering / dilution of economics

To raise funds, Kiora may need to license assets on terms that reduce future upside.

Scope
KIO-301 outside partnered territory, KIO-101, KIO-104
Materiality
medium
Collaboration revenue recognition
Revenue timing can be lumpy and driven by contract terms rather than product sales
Clinical trial accruals and R&D estimates
Quarterly operating expense volatility
Going-concern assessment
Material for liquidity and valuation analysis
Stock-based compensation
Affects operating loss and non-cash expense

KIORA PHARMACEUTICALS INC

KPRX · Pharmaceutical Preparations

Keros Therapeutics, Inc.

KROS · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Kura Oncology, Inc.

KURA · Pharmaceutical Preparations

: 28/04/2026